Condition focus: Dry Eye Disease & Meibomian Gland Dysfunction (MGD): 

Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) with seven treatment visits and four maintenance visits on average (medians), and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms. Adverse events, most typically redness or swelling, were found for 13% of patients. No serious adverse events were found. 

Conclusions: Although preliminary, study results of intense-pulsed-light therapy treatment for dry eye syndrome caused by meibomian gland dysfunction are promising. A multisite clinical trial with a larger sample, treatment comparison groups, and randomized controlled trials is currently underway.

WaveFront Alignment: protocols differ, this study supports the broader rationale for light-based approaches to MGD. The Spectral WaveFront uses 670 nm and 810 nm in an ocular-specific geometry designed to support mitochondrial and inflammatory pathways relevant to eyelid and ocular-surface physiology.

Link to original research here